Axogen (AXGN) Director Amy McBride Sells Shares After Option Exercise

What Happened
Amy McBride, a director of Axogen, exercised 13,353 stock options and immediately sold the 13,353 underlying shares on August 11, 2026. The exercise price was $14.85 per share (cost $198,292) and the shares were sold at a weighted average price of $48.42 per share for total sale proceeds of $646,592, resulting in net proceeds of roughly $448,300 before taxes and fees. The sale was executed under a Rule 10b5-1 trading plan.

Key Details

• Transaction date: August 11, 2026; Form 4 filed August 12, 2026 (timely filing).
• Option exercise (Code M): 13,353 shares exercised at $14.85 each (total $198,292).
• Open-market sale (Code S): 13,353 shares sold at a weighted avg $48.42 ($646,592 total). Sales occurred at prices ranging $47.82–$49.02 per share (footnote F2).
• A related derivative disposition of 13,353 shares at $0 is reported (reflects conversion/exercise of the option).
• Sale was effected under a pre-established Rule 10b5-1 plan adopted May 12, 2026 (footnote F1).
• Vesting: the underlying options were fully vested as of May 14, 2018 (footnote F3).
• Shares owned after the transaction: not provided in the data here.

Context
This was effectively a cashless exercise: McBride converted vested options into shares and sold the shares the same day, a common way for insiders to realize gains or diversify. The sale was made under a 10b5-1 plan, which is a pre-arranged trading program and typically indicates a planned, non-timed sale rather than a spontaneous market-timing decision.